4.6 Article

Clinical performance evaluation of the Fluorecare? SARS-CoV-2 & Influenza A/B & RSV rapid antigen combo test in symptomatic individuals

Journal

JOURNAL OF CLINICAL VIROLOGY
Volume 161, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.jcv.2023.105419

Keywords

Antigen; SARS-CoV-2; Influenza; RSV; Multiplex; Combo; RAD

Categories

Ask authors/readers for more resources

Given the concurrent circulation of SARS-CoV-2, Flu A/B, and RSV during the winter season, a SARS-CoV-2+Flu A/B+RSV Combo Rapid test may be more relevant than Rapid Antigen Diagnostic tests targeting only SARS-CoV-2. This study assessed the clinical performance of the combo test compared to multiplex RT-qPCR and found that it had satisfactory sensitivity for Influenza A and B in samples with high viral load.
Background: A SARS-CoV-2+Flu A/B+RSV Combo Rapid test may be more relevant than Rapid Antigen Diagnostic (RAD) tests targeting only SARS-CoV-2 since we are facing a concurrent circulation of these viruses during the winter season. Objectives: To assess the clinical performance of a SARS-CoV-2+Flu A/B+RSV Combo test in comparison to a multiplex RT-qPCR. Study Design: Residual nasopharyngeal swabs issued from 178 patients were included. All patients, adults and children, were symptomatic and presented at the emergency department with flu-like symptoms. Characterization of the infectious viral agent was done by RT-qPCR. The viral load was expressed as cycle threshold (Ct). Samples were then tested using the multiplex RAD test Fluorecare (R). SARS-CoV-2 & Influenza A/B & RSV Antigen Combo Test. Data analysis was carried out using descriptive statistics. Results: The sensitivity of the test varies according to the virus, with the highest sensitivity observed for Influenza A (80.8.% [95%CI: 67.2 - 94.4]) and the lowest sensitivity observed for RSV (41.5% [95%CI: 26.2 - 56.8]). Higher sensitivities were observed for samples with high viral loads (Ct < 20) and decrease with low viral loads. The specificity for SARS-CoV-2, RSV and Influenza A and B was >95%. Conclusions: The Fluorecare (R) combo antigenic presents satisfying performance in real-life clinical setting for Influenza A and B in samples with high viral load. This could be useful to allow a rapid (self-)isolation as the transmissibility of these viruses increase with the viral load. According to our results, its use to rule-out SARSCoV-2 and RSV infection is not sufficient.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available